Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17847971 | 1.00 | PPARG (0.42) | PPARGTSHRLCKL3MBTL1ALDH1A1 | |
| SCHEMBL17847730 | 0.93 | PPARG (0.42) | PPARGTSHRL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL17847728 | 0.93 | PPARG (0.42) | PPARGTSHRL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL22215267 | 0.91 | PPARG (0.40) | PPARGTSHRL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL19857213 | 0.91 | PPARG (0.47) | PPARGTSHRALDH1A1KDM4EMAPT | |
| SCHEMBL17853928 | 0.91 | PPARG (0.47) | PPARGTSHRALDH1A1KDM4EMAPT | |
| SCHEMBL19017441 | 0.89 | PPARG (0.42) | PPARGTSHRLCKL3MBTL1ALDH1A1 | |
| SCHEMBL17847950 | 0.86 | PPARG (0.46) | PPARGTSHRLCKL3MBTL1ALDH1A1 | |
| SCHEMBL17847945 | 0.86 | PPARG (0.46) | PPARGTSHRLCKL3MBTL1ALDH1A1 | |
| SCHEMBL17854864 | 0.86 | PPARG (0.46) | PPARGTSHRLCKL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | claimed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| CN-107466232-B | Methods of treating or preventing RAS-mediated diseases | ADT制药有限责任公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3233071-B1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS LLC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180251443-A9 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC | 2018-09-06 | — | — | US | disclosed |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3233071-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100546-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251443-A9 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885TSHR 697/4885LCK 1962/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | PPARG 1654/4885TSHR 697/4885LCK 1962/4885 |
| US-20180044314-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885TSHR 697/4885LCK 1962/4885 |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885TSHR 697/4885LCK 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.